基于PD-1/PD-L1联合治疗在前列腺癌中的研究进展OA北大核心CSTPCD
Research progress of PD-1/PD-L1 in prostate cancer immunotherapy
前列腺癌是男性第二大常见癌症,也是男性癌症死亡的第五大原因,其传统治疗方法包括根治性前列腺癌切除术、化学治疗、雄激素剥夺治疗等,虽然起初有治疗反应,但有部分患者最终会进展到去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC).人体免疫系统虽然能发挥监测功能,及时杀死肿瘤细胞,但肿瘤细胞在演变过程中也随之表达PD-L1,其与T细胞上的PD-1结合,能抑制T细胞功能,最终诱导免疫逃逸.对PD-1/PD-L1 在前列腺癌免疫逃逸机制中的深入研究,可能对往后将基于PD-1/PD-L1的免疫治疗应用于前列腺癌治疗提供新的治疗策略.本文将对PD-1/PD-L1在前列腺癌免疫治疗中的最新研究进展作一综述.
Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer deaths in men.Al-though there is an initial response to traditional treatments which include radical prostatectomy,chemotherapy,androgen depriva-tion therapy,and so on,some patients eventually progress to castration-resistant prostate cancer.The human immune system can perform a monitoring function to kill tumor cells promptly,however,tumor cells also express PD-L1 as they evolve,which binds to PD-1 on T cells and can inhibit T cell function,ultimately inducing immune evasion.The in-depth study of PD-1/PD-L1 in the mechanism of immune evasion in prostate cancer may provide new therapeutic strategies for the future application of PD-1/PD-L1-based immunotherapy in prostate cancer treatment.In this paper,we will review the latest research progress of PD-1/PD-L1 in prostate cancer immunotherapy.
施干;王飞
海南医学院附属海南医院海南省人民医院泌尿外科,海南 海口 570311
临床医学
前列腺癌PD-1/PD-L1免疫治疗预后
Prostate cancerPD-1/PD-L1ImmunotherapyPrognosis
《海南医学院学报》 2024 (010)
795-800 / 6
This study was supported by Hainan Province Key Research and Development Project Fund(ZDYF2021SHFZ096) 海南省重点研发项目基金(ZDYF2021SHFZ096)
评论